RxDoctor Payments Data

Julio Urena, MD

Internal Medicine · Clifton, NJNPI 1356302186

Payments from drug & device makers

$829in general payments, 2019–2025

Across 68 payments — averaging $12.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$534
  • GSK$61
  • Amgen$57
  • Octapharma USA, Inc.$49
  • Radius Health, Inc.$42
  • Medtronic$32
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$829100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.52$534
GSK1$61
Amgen(2 entities)4$57
Octapharma USA, Inc.2$49
Radius Health, Inc.3$42
Medtronic2$32
Johnson & Johnson2$31
Merck1$12
Organon1$10

How this compares

$829 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$28,224
Medicare patients
68
Services billed
741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$159,903
JanuviaSitagliptin Phosphate64$73,904
EliquisApixaban51$40,809
LinzessLinaclotide47$36,198
FarxigaDapagliflozin Propanediol15$11,128
Icosapent Ethyl11$7,136
XareltoRivaroxaban12$6,572
Rosuvastatin Calcium213$6,268
Diclofenac Potassium42$5,205
Incruse ElliptaUmeclidinium Bromide11$4,178
Atorvastatin Calcium343$4,133
Pravastatin Sodium207$3,791
Metoprolol Succinate211$3,460
Metformin Hcl401$3,101
Losartan Potassium221$2,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$12$73,90464 claims
Johnson & JohnsonXarelto$31$6,57212 claims
GSKIncruse Ellipta$61$4,17811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →